Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34786 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Yoo-Na Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.
- Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Clinical Epidemiology & Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea.
ORCID-Profile: Jung-Yun Lee
Zitieren
APA
Kim, Y. N., Joung, J. G., Park, E., Kim, J. W., Lee, J. B., Lim, J., Kim, S., Choi, C. H., Kim, H. S., Chung, J., Kim, B. G., & Lee, J. Y. (2024). Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”. International Journal of Cancer. https://doi.org/10.1002/ijc.34786
Vancouver
Kim YN, Joung JG, Park E, Kim JW, Lee JB, Lim J, et al. Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”. International Journal of Cancer. 2024. doi:10.1002/ijc.34786
BibTeX
@article{Kim2024,
author = {Kim, Yoo-Na and Joung, Je-Gun and Park, Eunhyang and Kim, Jae-Weon and Lee, Jung Bok and Lim, Jinyeong and Kim, Sunghoon and Choi, Chel Hun and Kim, Hee Seung and Chung, Jongsuk and Kim, Byoung-Gie and Lee, Jung-Yun},
title = {Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34786}
}
EUVIMED